antiretroviral therapy cohort collaboration (ART-CC), Lanoy E, May M, Mocroft A, Phillip A, Justice A, et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS. 23 oct 2009;23(16):2199‑208. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19779320
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JAC, Egger M, May M, Grabar S, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis. 15 avr 2009;48(8):1138‑51. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19275498
Antiretroviral Therapy Cohort Collaboration, Zwahlen M, Harris R, May M, Hogg R, Costagliola D, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol. 9 déc 2009;38(6):1624‑33. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19820106
Chaix M-L, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS. 27 mars 2009;23(6):717‑24. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19279445
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 24 sept 2009;23(15):2029‑37. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19531926
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, et al. Incidence and risk factors of HIV-related non-Hodgkin’s lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009;14(8):1065‑74. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20032536
Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, et al. Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. J Acquir Immune Defic Syndr. 1 févr 2009;50(2):206‑14. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19131886
Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS. 1 juin 2009;23(9):1163‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19444075
Guiguet M, Boué F, Cadranel J, Lang J-M, Rosenthal E, Costagliola D, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. déc 2009;10(12):1152‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19818686
Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, et al. CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3. Antivir Ther. 2009;14(3):451‑7. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19474479
Hernán MA, McAdams M, McGrath N, Lanoy E, Costagliola D. Observation plans in longitudinal studies with time-varying treatments. Stat Methods Med Res. févr 2009;18(1):27‑52. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19036915
Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, et al. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates. HIV Med. avr 2009;10(4):236‑45. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19178591
Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 24 août 2009;23(13):1743‑53. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19571723
Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, et al. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr. 1 nov 2009;52(3):357‑63. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19668084
Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, et al. Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl. AIDS. 24 sept 2009;23(15):1997‑2004. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19654499
Potard V, Weiss L, Lamontagne F, Rouveix E, Beck-Wirth G, Drogoul-Vey M-P, et al. Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005. J Acquir Immune Defic Syndr. 1 nov 2009;52(3):422‑6. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19521249
When To Start Consortium, Sterne JAC, May M, Costagliola D, de Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (London, England). 18 avr 2009;373(9672):1352‑63. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19361855
